IP Library › Granted Patent US 12,685,785
Granted Patent B2
US 12,685,785 · App. 18/327,728 · Granted Jul 21, 2026

Polynucleotides encoding propionyl-CoA carboxylase alpha and beta subunits for the treatment of propionic acidemia

Inventors: Lei Jiang (Cambridge, MA); Lin Tung Guey (Lexington, MA); Paolo G. V. Martini (Boston, MA); Vladimir Presnyak (Manchester, NH)
Assignee: ModernaTX, Inc.
A61K48/0033A61K9/1271A61K38/53A61P3/00C12Y604/01003
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,685,785
App. No.
18/327,728
Filed
Jun 1, 2023
Granted
Jul 21, 2026
Kind
B2
Examiner
POPA, ILEANA
Art Unit
1633
USPC
514/44R
Abstract

This disclosure relates to mRNA therapy for the treatment of propionic acidemia (PA). mRNAs for use in the invention, when administered in vivo, encode human propionyl-CoA carboxylase alpha (PCCA) and/or human propionyl-CoA carboxylase beta (PCCB), and isoforms thereof, functional fragments thereof, and fusion proteins comprising PCCA and/or PCCB. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of propionyl-CoA carboxylase (PCC) expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of disease-associated toxic metabolites associated with deficient PCCA or PCCB activity, in subjects.

Claims (53)

1 . A messenger RNA (mRNA) comprising:

(i) a 5′-terminal cap;

(ii) a 5′ untranslated region (UTR);

(iii) an open reading frame (ORF) encoding the propionyl-CoA carboxylase alpha (PCCA) polypeptide set forth in SEQ ID NO:1, wherein the ORF has at least 93% sequence identity to the nucleic acid sequence set forth in SEQ ID NO:11;

(iv) a 3′ UTR; and

(v) a poly-A-region.

2 . The mRNA of claim 1 , wherein the ORF has at least 95% sequence identity to the nucleic acid sequence set forth in SEQ ID NO:11.

3 . The mRNA of claim 1 , wherein the ORF has at least 98% sequence identity to the nucleic acid sequence set forth in SEQ ID NO:11.

4 . The mRNA of claim 1 , wherein the ORF has at least 99% sequence identity to the nucleic acid sequence set forth in SEQ ID NO:11.

5 . The mRNA of claim 1 , wherein the ORF has the nucleic acid sequence set forth in SEQ ID NO: 11.

6 . The mRNA of claim 1 , wherein the 5′ UTR comprises the nucleic acid sequence set forth in SEQ ID NO:199.

7 . The mRNA of claim 1 , wherein the 3′ UTR comprises the nucleic acid sequence set forth in SEQ ID NO:178.

8 . The mRNA of claim 1 , wherein the 5′ UTR comprises the nucleic acid sequence set forth in SEQ ID NO:199, and wherein the 3′ UTR comprises the nucleic acid sequence set forth in SEQ ID NO:178.

9 . The mRNA of claim 1 , comprising the nucleic acid sequence set forth in SEQ ID NO:203.

10 . The mRNA of claim 1 , wherein the poly-A region is at least 100 nucleotides in length.

11 . The mRNA of claim 1 , wherein all of the uracils are N1-methylpseudouracils.

12 . The mRNA of claim 5 , wherein the poly-A region is at least 100 nucleotides in length.

13 . The mRNA of claim 5 , wherein all of the uracils are N1-methylpseudouracils.

14 . The mRNA of claim 9 , wherein the poly-A region is at least 100 nucleotides in length.

15 . The mRNA of claim 9 , wherein all of the uracils are N1-methylpseudouracils.

16 . The mRNA of claim 14 , wherein all of the uracils are N1-methylpseudouracils.

17 . A pharmaceutical composition comprising a first mRNA and a second mRNA,

wherein the first mRNA comprises (i) a first 5′-terminal cap, (ii) a first 5′ UTR, (iii) a first ORF encoding the PCCA polypeptide set forth in SEQ ID NO:1, wherein the ORF has at least 93% sequence identity to the nucleic acid sequence set forth in SEQ ID NO:11, (iv) a first 3′ UTR, and (v) a first poly-A-region, and

wherein the second mRNA comprises (i) a second 5′-terminal cap, (ii) a second 5′ UTR, (iii) a second ORF encoding the PCCB polypeptide set forth in SEQ ID NO:15, wherein the ORF has at least 93% sequence identity to the nucleic acid sequence set forth in SEQ ID NO:25, (iv) a second 3′ UTR, and (v) a second poly-A-region.

18 . The pharmaceutical composition of claim 17 , wherein the first ORF has at least 95% sequence identity to the nucleic acid sequence set forth in SEQ ID NO: 11, and wherein the second ORF has at least 95% sequence identity to the nucleic acid sequence set forth in SEQ ID NO:25.

19 . The pharmaceutical composition of claim 17 , wherein the first ORF has at least 98% sequence identity to the nucleic acid sequence set forth in SEQ ID NO: 11, and wherein the second ORF has at least 98% sequence identity to the nucleic acid sequence set forth in SEQ ID NO:25.

20 . The pharmaceutical composition of claim 17 , wherein the first ORF has at least 99% sequence identity to the nucleic acid sequence set forth in SEQ ID NO: 11, and wherein the second ORF has at least 99% sequence identity to the nucleic acid sequence set forth in SEQ ID NO:25.

21 . The pharmaceutical composition of claim 17 , wherein the first ORF has to the nucleic acid sequence set forth in SEQ ID NO:11, and wherein the second ORF has the nucleic acid sequence set forth in SEQ ID NO:25.

22 . The pharmaceutical composition of claim 17 , wherein the first 5′ UTR comprises the nucleic acid sequence set forth in SEQ ID NO: 199, wherein the first 3′ UTR comprises the nucleic acid sequence set forth in SEQ ID NO:178, wherein the second 5′ UTR comprises the nucleic acid sequence set forth in SEQ ID NO: 199, and wherein the second 3′ UTR comprises the nucleic acid sequence set forth in SEQ ID NO:178.

23 . The pharmaceutical composition of claim 17 , wherein the first mRNA comprises the nucleic acid sequence set forth in SEQ ID NO:203, and wherein the second mRNA comprises the nucleic acid sequence set forth in SEQ ID NO:205.

24 . The pharmaceutical composition of claim 17 , wherein the first poly-A region is at least 100 nucleotides in length, and wherein the second poly-A region is at least 100 nucleotides in length.

25 . The pharmaceutical composition of claim 17 , wherein all of the uracils of the first mRNA are N1-methylpseudouracils, and wherein all of the uracils of the second mRNA are N1-methylpseudouracils.

26 . The pharmaceutical composition of claim 21 , wherein the first poly-A region is at least 100 nucleotides in length, and wherein the second poly-A region is at least 100 nucleotides in length.

27 . The pharmaceutical composition of claim 21 , wherein all of the uracils of the first mRNA are N1-methylpseudouracils, and wherein all of the uracils of the second mRNA are N1-methylpseudouracils.

28 . The pharmaceutical composition of claim 23 , wherein the first poly-A region is at least 100 nucleotides in length, and wherein the second poly-A region is at least 100 nucleotides in length.

29 . The pharmaceutical composition of claim 23 , wherein all of the uracils of the first mRNA are N1-methylpseudouracils, and wherein all of the uracils of the second mRNA are N1-methylpseudouracils.

30 . The pharmaceutical composition of claim 28 , wherein all of the uracils of the first mRNA are N1-methylpseudouracils, and wherein all of the uracils of the second mRNA are N1-methylpseudouracils.

31 . The pharmaceutical composition of claim 17 , wherein the first mRNA and the second mRNA are encapsulated into a lipid nanoparticle.

32 . The pharmaceutical composition of claim 31 , wherein the lipid nanoparticle comprises an ionizable lipid, a structural lipid, a phospholipid, and a polyethylene glycol (PEG)-modified lipid.

33 . The pharmaceutical composition of claim 32 , wherein the ionizable lipid is

or a salt thereof, wherein the structural lipid is cholesterol, wherein the phospholipid is 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) or 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and wherein the PEG-modified lipid is 1,2-dimyristoyl-sn-glycerol methoxypolyethylene glycol (PEG-DMG) or Compound I

34 . The pharmaceutical composition of claim 21 , wherein the first mRNA and the second mRNA are encapsulated into a lipid nanoparticle.

35 . The pharmaceutical composition of claim 34 , wherein the lipid nanoparticle comprises an ionizable lipid, a structural lipid, a phospholipid, and a polyethylene glycol (PEG)-modified lipid.

36 . The pharmaceutical composition of claim 35 , wherein the ionizable lipid is

or a salt thereof, wherein the structural lipid is cholesterol, wherein the phospholipid is 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) or 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and wherein the PEG-modified lipid is 1,2-dimyristoyl-sn-glycerol methoxypolyethylene glycol (PEG-DMG) or Compound I

37 . The pharmaceutical composition of claim 25 , wherein the first mRNA and the second mRNA are encapsulated into a lipid nanoparticle.

38 . The pharmaceutical composition of claim 37 , wherein the lipid nanoparticle comprises an ionizable lipid, a structural lipid, a phospholipid, and a polyethylene glycol (PEG)-modified lipid.

39 . The pharmaceutical composition of claim 38 , wherein the ionizable lipid is

or a salt thereof, wherein the structural lipid is cholesterol, wherein the phospholipid is 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) or 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and wherein the PEG-modified lipid is 1,2-dimyristoyl-sn-glycerol methoxypolyethylene glycol PEG-DMG) or Compound I

40 . The pharmaceutical composition of claim 27 , wherein the first mRNA and the second mRNA are encapsulated into a lipid nanoparticle.

41 . The pharmaceutical composition of claim 40 , wherein the lipid nanoparticle comprises an ionizable lipid, a structural lipid, a phospholipid, and a polyethylene glycol (PEG)-modified lipid.

42 . The pharmaceutical composition of claim 41 , wherein the ionizable lipid is

or a salt thereof, wherein the structural lipid is cholesterol, wherein the phospholipid is 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) or 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and wherein the PEG-modified lipid is 1,2-dimyristoyl-sn-glycerol methoxypolyethylene glycol (PEG-DMG) or Compound I

Assignments (2)
SECURITY INTEREST Recorded Nov 19, 2025
From: MODERNATX, INC.
To: ARES CAPITAL CORPORATION, AS AGENT
Reel/Frame 073634/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 21, 2023
From: JIANG, LEI; GUEY, LIN TUNG; MARTINI, PAOLO G. V.; PRESNYAK, VLADIMIR
To: MODERNATX, INC.
Reel/Frame 064011/0122 →
Continuity (7)
Continuation 16765632 · Nov 21, 2018
Provisional Application 62747356 · Oct 18, 2018
Provisional Application 62693552 · Jul 3, 2018
Provisional Application 62663024 · Apr 26, 2018
Provisional Application 62614787 · Jan 8, 2018
Provisional Application 62590199 · Nov 22, 2017
Related Publication 20240024506A1 · Jan 25, 2024
References Cited (96)
US 8691966B2 · Kariko et al. · 2014 [cited by applicant]
US 20140155468A1 · Gregory et al. · 2014 [cited by applicant]
US 20180126003A1 · Ingmar · 2018 [cited by applicant]
US 20180126005A1 · Fotin-Mleczek · 2018 [cited by applicant]
US 20180221402A1 · Prieve et al. · 2018 [cited by applicant]
US 20190175759A1 · Fotin-Mleczek et al. · 2019 [cited by applicant]
US 20200165593A1 · Sobolov-Jaynes · 2020 [cited by applicant]
US 20220265856A1 · Jiang et al. · 2022 [cited by applicant]
US 20240216288A1 · Benenato et al. · 2024 [cited by applicant]
US 20240316165A1 · Attarwala et al. · 2024 [cited by applicant]
WO WO1995027512 · 1995 [cited by applicant]
WO WO2009030481 · 2009 [cited by applicant]
WO WO2009127230 · 2009 [cited by applicant]
WO WO2013151665 · 2013 [cited by applicant]
WO WO2013151666 · 2013 [cited by applicant]
WO WO2014152513 · 2014 [cited by applicant]
WO WO2014160243 · 2014 [cited by applicant]
WO WO2015017519 · 2015 [cited by applicant]
WO WO2016118697 · 2016 [cited by applicant]
WO WO2016179138 · 2016 [cited by applicant]
WO WO2017049245 · 2017 [cited by applicant]
WO WO2017062513 · 2017 [cited by applicant]
WO WO2017070616 · 2017 [cited by applicant]
WO WO2017070626 · 2017 [cited by applicant]
WO WO2017100551 · 2017 [cited by applicant]
WO WO2017147720 · 2017 [cited by applicant]
WO WO2017153936 · 2017 [cited by applicant]
WO WO2017191274 · 2017 [cited by applicant]
WO WO2017192761 · 2017 [cited by applicant]
WO WO2017201349 · 2017 [cited by applicant]
WO WO2018204603 · 2018 [cited by applicant]
WO WO2018232357 · 2018 [cited by applicant]
WO WO2019018765 · 2019 [cited by applicant]
WO WO2020061295 · 2020 [cited by applicant]
WO WO2020072451 · 2020 [cited by applicant]
WO WO2020264353 · 2020 [cited by applicant]
WO WO2021076797 · 2021 [cited by applicant]
WO WO2022204380 · 2022 [cited by applicant]
WO WO2023287751 · 2023 [cited by applicant]
Alignment_SEQ 11 to SEQ 5 in U.S. Appl. No. 18/578,052, filed 2025. [cited by examiner]
Alignment_SEQ 25 to SEQ 6 in U.S. Appl. No. 18/578,052, filed 2025. [cited by examiner]
Pardi et al., J. Control. Rel., 2015, 217: 345-351. [cited by examiner]
Alignment_Flotin-Mleczek_SEQ 25, 2025. [cited by examiner]
U.S. Appl. No. 16/765,632, filed May 20, 2020, Lei Jiang. [cited by applicant]
U.S. Appl. No. 16/631,607, filed Jan. 16, 2020, Susan Sobolov-Jaynes. [cited by applicant]
Chandler et al., “Efficacy of Adeno-associated Viral Gene Therapy as a Treatment for Methylmalonic and Propionic Acidemia,” Dissertation for the degree of Doctor of Philosophy, The Faculty of the Columbian College of Ar… [cited by applicant]
Charbit-Henrion et al., “Early and Late Complications After Liver Transplantation for Propionic Acidemia in Children: A Two Centers Study,” American Journal of Transplantation, Mar. 2015, 15(3):786-791. [cited by applicant]
Critelli et al., “Liver Transplantation for Propionic Acidemia and Methylmalonic Acidemia: Perioperative Management and Clinical Outcomes,” Liver Transplantation, Sep. 2018, 24(9):1260-1270. [cited by applicant]
GenBank Accession No. NM_000282.3, “ [cited by applicant]
GenBank Accession No. NM_000532.4, “ [cited by applicant]
GenBank Accession No. NM_001127692.2, “ [cited by applicant]
GenBank Accession No. NM_001178004.1, “ [cited by applicant]
GenBank Accession No. NM_001178014.1, “ [cited by applicant]
GenPept Accession No. NP_000273.2, “propionyl-CoA carboxylase alpha chain, mitochondrial isoform a precursor [ [cited by applicant]
GenPept Accession No. NP_000523.2, “propionyl-CoA carboxylase beta chain, mitochondrial isoform 1 precursor [ [cited by applicant]
GenPept Accession No. NP_001121164.1, “propionyl-CoA carboxylase alpha chain, mitochondrial isoform b [ [cited by applicant]
GenPept Accession No. NP_001171475.1, “propionyl-CoA carboxylase alpha chain, mitochondrial isoform c precursor [ [cited by applicant]
GenPept Accession No. NP_001171485.1, “propionyl-CoA carboxylase beta chain, mitochondrial isoform 2 precursor [ [cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2022/021713, mailed on Oct. 5, 2023, 7 pages. [cited by applicant]
International Preliminary Report on Patentability in International Application No. PCT/US2022/036769, mailed on Jan. 25, 2024, 10 pages. [cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2022/021713, mailed on Jul. 22, 2022, 15 pages. [cited by applicant]
International Search Report and Written Opinion in International Application No. PCT/US2022/036769, mailed on Nov. 22, 2022, 18 pages. [cited by applicant]
Jiang et al., “Dual mRNA Therapy Restores Metabolic Function in Long-term Studies in Mice with Propionic Acidemia,” Nature Communications, Oct. 21, 2020, 11(5339):1-10. [cited by applicant]
Jiang et al., “Supplementary data to: Dual mRNA Therapy Restores Metabolic Function in Long-term Studies in Mice with Propionic Acidemia,” Nature Communications, Oct. 21, 2020, 11(5339), 22 pages. [cited by applicant]
Lomash et al., “Successfully Navigating Food and Drug Administration Orphan Drug and Rare Pediatric Disease Designations for AAV9-hPCCA Gene Therapy: The National Institutes of Health Platform Vector Gene Therapy Experi… [cited by applicant]
McKusick et al., “OMIM 232000—Ropionyl-CoA Carboxylase, Alpha Subunit; PCCA,” Jun. 3, 1986, last updated Dec. 20, 2021, 11 pages. [cited by applicant]
McKusick et al., “OMIM 232050—Propionyl-CoA Carboxylase, Beta Subunit; PCCB,” Jun. 24, 1986, last updated Nov. 28, 2008, 11 pages. [cited by applicant]
Quintero et al., “The Role of Liver Transplantation in Propionic Acidemia,” Liver Transplantation, Dec. 2018, 24(12):1736-1745. [cited by applicant]
Silva et al., “Liver Transplantation for Propionic Acidemia,” Journal of Pediatric Gastroenterology and Nutrition, Mar. 2017, 64(3):e73-76. [cited by applicant]
Vara et al., “Liver transplantation for propionic acidemia in children,” Liver Transplantation, Jun. 2011, 17(6):661-667. [cited by applicant]
U.S. Appl. No. 16/765,632, 20220265856, May 20, 2020, Jiang. [cited by applicant]
U.S. Appl. No. 16/631,607, 20200165593, Jan. 16, 2020, Sobolov-Jaynes. [cited by applicant]
U.S. Appl. No. 18/578,052, filed Jan. 10, 2024, Attarwala. [cited by applicant]
U.S. Appl. No. 18/282,640, filed Sep. 18, 2023, Benenato. [cited by applicant]
SCV Search Results Details for U.S. Appl. No. 16/765,632 and Search Result 20240905, “Sequence alignment, BFB44649 standard; RNA; 1620 BP,” first entry on Apr. 5, 2018, retrieved on Jan. 1, 2025, 3 pages. [cited by applicant]
U.S. Appl. No. 18/578,052, 20240316165, Jan. 10, 2024, Attarwala. [cited by applicant]
U.S. Appl. No. 18/282,640, 20240216288, Sep. 18, 2023, Benenato. [cited by applicant]
Guenzel et al., “Generation of a Hypomorphic Model of Propionic Acidemia Amenable to Gene Therapy Testing,” Molecular Therapy, Jul. 2013, 21(7):1316-1323. [cited by applicant]
Clavero et al., “Functional characterization of PCCA mutations causing propionic acidemia”, Molecular Basis of Disease, Nov. 2002, 1588(2):119-125. [cited by applicant]
Darvish-Damavandi et al., “Towards the development of an enzyme replacement therapy for the metabolic disorder propionic acidemia”, Molecular Genetics and Metabolism Reports, Jul. 2016, 8:51-60. [cited by applicant]
Dreyfus et al., “The Poly(A) Tail of mRNAs: Bodyguard in Eukaryotes, Scavenger in Bacteria,” Cell, Nov. 2002, 111:611-613. [cited by applicant]
Hanson et al., “Codon optimality, bias and usage in translation and mRNA decay”, Nat. Rev. Mol. Cell Biol., Oct. 2017, 19(1):20-30. [cited by applicant]
Kurokawa et al., “Development of New Treatment Method of Propionic Acidemia (PA),” Talk, 3T21-6, 2008, 3 pages (with English Translation). [cited by applicant]
Lamhonwah et al., “Correction of the Metabolic Defect in Propionic Acidemia Fibroblasts by Microinjection of a Full-Length cDNA or RNA Transcript Encoding the Propionyl-CoA Carboxylase beta Subunit,” Genomics, 1994, 19(… [cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2018/043089, dated Jan. 30, 2020, 8 pages. [cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2018/062283, dated Jun. 4, 2020, 20 pages. [cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2018/043089, dated Oct. 19, 2018, 16 pages. [cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2018/062283, dated May 17, 2019, 35 pages. [cited by applicant]
Perez-Cerda et al., “Functional analysis of PCCB mutations causing propionic acidemia based on expression studies in deficient human skin fibroblasts”, Biochimica Et Biophysica Acta. Molecular Basis of Disease, Apr. 200… [cited by applicant]
Perez-Cerda et al., “Functional Analysis of PCCB Mutations Causing Propionic Acidemia Based on Expression Studies in Deficient Human Skin Fibroblasts,” Biochimica et Biophysica Acta, May 2003, 1638(1):43-49. [cited by applicant]
Rodriguez-Pombo et al., “Transfection Screening for Defects in the PCCA and PCCB Genes Encoding Propionyl-CoA Carboxylase Subunits”, Molecular Genetics and Metabolism, 2002, 75:276-279. [cited by applicant]
Shchelochkov et al., “Propionic Acidemia” GeneReviews, 2016, 30 pages. [cited by applicant]
Tavernier et al., “mRNA as gene therapeutic: How to control protein expression”, Journal of Controlled Release, Oct. 2010, 150(3):240-241. [cited by applicant]
Wongkittichote et al., “Propionyl-CoA carboxylase—A review”, Molecular Genetics and Metabolism, Oct. 2017, 122(4):145-152. [cited by applicant]
Yamamoto et al., “Current prospects for mRNA gene delivery”, European Journal of Pharmaceutics and Biopharmaceutics, Oct. 2008, 71(3):484-489. [cited by applicant]
Youn et al., “Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy”, Expert Opinion on Biological Therapy, Jun. 2015, 15(9):1337-1348. [cited by applicant]